Streamlining Treatment Complexity in Schizophrenia: Insights From Real-World Practice

This expert commentary examines how polypharmacy may develop and persist in schizophrenia care, drawing on real-world evidence to explore its prevalence, potential clinical burden, and barriers. The article proposes an evidence-informed framework for treatment streamlining organized around clinical themes and concepts from guidelines. 

Introduction

Schizophrenia is a debilitating mental disorder with an estimated prevalence of up to 1.6% among adults in the United States.¹ Despite decades of advancements in antipsychotic therapy, real-world prescribing patterns for schizophrenia remain complex.^2,3 While antipsychotic medications are often the first-line treatment for schizophrenia, many patients are either not fully adherent or choose to discontinue treatment, thereby increasing the risk of relapse or hospitalization.¹ In other patients, efforts to address schizophrenia symptoms or help manage side effects may result in switching antipsychotic medications or adding additional medications, which may lead to associated increases in medical treatment costs.¹ 

Antipsychotic polypharmacy—the concurrent use of two or more antipsychotics—is observed in 10-40% of patients despite limited evidence for its efficacy.^1,4-6 Although antipsychotic polypharmacy may start as a response to challenging symptoms, acute destabilization, or to target specific comorbidities, ambiguity remains regarding its use, duration of use, and appropriate criteria for transitioning back to monotherapy.^6,7 

A growing body of evidence underscores the risks associated with the use of multi-medication regimens, including increased side-effect burden, cognitive dysfunction, risk of drug-drug interactions, poor adherence, and increased medical costs.⁷ Evidence from both US and international studies indicates polypharmacy and limited use of structured deprescribing processes, even in the context of poor adherence or high health care utilization.^1,8 These findings highlight the potential for treatment burden to accumulate over time when regimen complexity is not actively monitored or reassessed. 

This article synthesizes real-world findings on antipsychotic prescribing patterns and potential structured treatment approaches to examine how treatment complexity develops in schizophrenia and highlights potential considerations for streamlining treatment.

Real-World Evidence: Prevalence, Persistence, and Patterns of Use

Antipsychotic polypharmacy is utilized across treatment settings, despite limited evidence supporting long-term benefits for most patients.^1,4-6 In a large US-based systematic review of prescribing patterns across commercial and Medicare claims from 81 observational, real-world studies published between January 2008 and June 2018 examining treatment adherence in patients with schizophrenia, nearly 30% of patients receiving oral antipsychotics were treated with combination regimens, and medication changes often occurred within the first 90 days of treatment.¹ More complex psychotropic regimens, including antipsychotic combinations, were associated with higher overall health care costs, reflecting the broader burden of multi-drug management.¹   

Longitudinal data from national registries, including 29,696 patients with schizophrenia in Denmark, show that more than half of individuals with schizophrenia receive antipsychotic polypharmacy at some point during their illness trajectory.⁴ Although the prevalence of antipsychotic polypharmacy decreased from 2005 to 2024, about 30% of schizophrenia patients remained exposed to antipsychotic polypharmacy in recent years.⁴  

A retrospective analysis of 2,177 patients with schizophrenia in Japan found that patients were frequently discharged on a combination antipsychotic regimen initiated during an acute inpatient stay.⁸ These patients were also more likely to receive concomitant psychotropic medications, compared to those discharged only on antipsychotic monotherapy.^8,9 Though the study did not assess reasons for polypharmacy persistence, the chronic nature of schizophrenia may contribute to these patterns, as clinicians may continue adding medications in response to symptoms.^6,7  

These findings illustrate the dynamic nature of real-world prescribing practices in schizophrenia and highlight the need for structured follow-up.

Clinical Burden: Polypharmacy, Side Effects, and Nonadherence

Evidence has associated psychotropic polypharmacy, including antipsychotic polypharmacy, with a greater subjective and objective burden of adverse effects, which may include cardiometabolic effects, cognitive changes, gastrointestinal effects, sedation, sexual dysfunction, and the broader functional impact.^7,10,11

Adherence may be another concern.⁷ Overall nonadherence rates of 40%-60% have been reported among individuals with schizophrenia, and poor treatment adherence related to polypharmacy substantially increases the likelihood of medication discontinuation, relapse, and rehospitalization.^7,12 

Consideration for  Deprescribing and Treatment Streamlining

Despite increasing attention to treatment simplification and considerations regarding the long-term use of antipsychotic polypharmacy, combination regimens are frequently encountered in psychiatric practice.^1,4-6 Expert guidance emphasizes that when initiating antipsychotic polypharmacy, the patient’s symptomatology and clinical status should be clearly documented, and regular reassessment is recommended to assess treatment response.³ A structured method or tool may be employed to monitor for medication-related side effects.^5,9 Antipsychotic polypharmacy may be initiated during periods of acute illness or symptom exacerbation, when clinicians seek to address acute schizophrenia symptoms or tolerability, which usually occurs in the inpatient setting.⁷ When baseline symptomatology or treatment rationale at the time of polypharmacy initiation is unclear, evaluating the potential clinical benefits of ongoing combination therapy becomes more challenging.⁶ As a result, the clinical rationale and benefits of ongoing polypharmacy may be more difficult to assess during subsequent treatment decisions.⁶ Additionally, uncertainty remains regarding the optimal duration of polypharmacy and appropriate criteria for transition back to monotherapy, which may complicate subsequent efforts to simplify treatment in ongoing care.⁷ 

Fragmented care—defined as the delivery of health services across multiple providers or settings without adequate coordination or communication—may introduce additional challenges.¹¹ Fragmented transitions between levels of care are recognized as potential points of disconnect for medication continuity, and evidence from general health systems indicates that medication reconciliation processes are often suboptimal at these transitions, potentially contributing to the persistence of these complex regimens.¹³ Limited interoperability of electronic health records, time constraints, and challenges in interdisciplinary communication may complicate efforts to reassess and streamline complex medication regimens across care settings.¹⁴

In addition, inadequate use of measurement-based care—objective measures to assess treatment response and adverse effects—also complicates evaluation of the ongoing benefits and risks of antipsychotic polypharmacy.⁷ 

Streamlining Treatment Complexity: Evidence-Informed Strategies

Synthesizing real-world data, pharmacologic insights, and treatment guidelines, several principles emerge for reducing antipsychotic burden.^2,6,7 

Clinical Assessment and Treatment Planning

A structured review of prior antipsychotic trials, dosing adequacy, side effects, adherence patterns, and comorbid psychotropic use may help clarify treatment strategies.⁷ At the outset of any treatment planning, clinicians should document target symptoms, expected duration, and criteria for maintenance, tapering, or discontinuation. Clear documentation facilitates later reassessment and may help reduce prescribing inertia.⁶ 

Adherence Assessment and Optimization

Confirming adherence is essential to evaluate a patient’s treatment response. Some considerations and approaches may include reviewing plasma drug levels and obtaining caregiver reports. 

Adverse Effect Management and Monitoring

Understanding the side effect profiles across antipsychotic agents may help determine appropriate treatment options and further elucidate optimal strategies. Combination therapy may increase adverse effects and drug-drug interactions.^7,9

Measurement-Based Care and Deprescribing

Quantifying symptoms, side effects, and functional outcomes over time may allow clinicians to better assess the patient and whether simplification is appropriate.⁷ Routine follow-ups provide opportunities for reassessment, especially after stabilization.⁶ Because the clinical rationale for polypharmacy may not be clearly documented, the rationale for continuing may be unclear, highlighting the importance of reassessment once stability is achieved.⁶

Patient-Centered and System-Level Supports

Shared decision-making involving the person diagnosed with schizophrenia and their carers should be employed whenever possible.² Patients' experiences of side effects and treatment complexity may influence their engagement with medication, and shared decision making can have an impact on adherence and perceived burden. It may help tailor treatment strategies to individual needs and preferences.² System-level interventions—including medication reconciliation, coordinated care transitions, and guideline-based clinician education—can meaningfully reduce treatment complexity, including communicating across inpatient teams, outpatient clinicians, case managers, and families to ensure treatment decisions are not made in isolation.^13,14

Conclusion

Treatment complexity, particularly polypharmacy, is an important consideration in schizophrenia care, often emerging from clinical necessity but perpetuated by prescribing inertia, structural barriers, and, in some instances, limited opportunities for reassessment. Real-world data highlight the need for more systematic approaches to documentation, monitoring, patient engagement, and coordinated care. 

Considerations for managing schizophrenia include, but are not limited to, adherence assessment and adverse event monitoring, which may indirectly inform polypharmacy considerations. Integrating measurement-based care, structured review processes, collaborative decision-making, and system-level supports within structured guideline frameworks may help reduce unnecessary treatment burden while promoting stability, tolerability, and long-term considerations.
 

References

1. Martin A, Bessonova L, Hughes R, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. Adv Ther. 2022;39(9):3933-3956.
2. Foster A, King J. Antipsychotic polypharmacy. Focus. 2020;18(4):375–385.
3. Kim JJ, Pae CU, Han C, et al. Exploring hidden issues in the use of antipsychotic polypharmacy in the treatment of schizophrenia. Clin Psychopharmacol Neurosci. 2021;19(4):600-609.
4. Højlund M, Rohde C, Gasse C, et al. Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: prevalence, time trends, and combinations. Eur Neuropsychopharmacol. 2025;100:4–12.
5. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. 3rd ed. American Psychiatric Association; 2021.
6. Lähteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273–1284.
7. Pae CU. Antipsychotic polypharmacy in treatment of schizophrenia; should or should not? Chonnam Med J. 2020;56(3):157–165.
8. Hashimoto N, Yasui-Furukori N, Hasegawa N, et al. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr. 2021;63:102744. -10
9. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–356.
10. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. 2018;17(1):3-11. doi:10.1002/wps.20509
11. Ijaz S, Bolea B, Davies S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18:275. doi: 10.1186/s12888-018-1848-y
12. National Committee for Quality Assurance. Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA). Accessed December 22, 2025. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/adherence-to-antipsychotic-medications-for-individuals-with-schizophrenia-saa/
13. Kern LM, Bynum JPW, Pincus HA. Care fragmentation, care continuity, and care coordination-how they differ and why it matters. JAMA Intern Med. 2024;184(3):236–237.
14. Wang J, Shen JY, Conwell Y, et al. Implementation considerations of deprescribing interventions: a scoping review. J Intern Med. 2024;295(4):436–507.

© 2026 Bristol-Myers Squibb Company. 
NS-US-2600085 08/26